STERIS plc (NYSE: STE) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
239.11
+1.64+0.69%
News
Up 0.7% — STERIS Q1 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 28.96 | EPS (ttm) | 8.20 | Insider Own | 0.45% | Shs Outstand | 97.46M | Perf Week | 3.97% |
| Market Cap | 23.14B | Forward P/E | 19.56 | EPS next Y | 12.14 | Insider Trans | -2.39% | Shs Float | 97.13M | Perf Month | 9.94% |
| Enterprise Value | 22.90B | PEG | 1.16 | EPS next Q | - | Inst Own | - | Short Float | 2.51% | Perf Quarter | 11.12% |
| Income | 803.07M | P/S | 3.83 | EPS this Y | 40.56% | Inst Trans | - | Short Ratio | 2.97 | Perf Half Y | -2.60% |
| Sales | 6.04B | P/B | 3.21 | EPS next Y | 8.93% | ROA | 8.28% | Short Interest | 2.44M | Perf YTD | -6.33% |
| Book/sh | - | P/C | 17.99 | EPS next 5Y | 8.82% | ROE | 11.27% | 52W High | 271.32 -11.87% | Perf Year | 7.35% |
| Cash/sh | - | P/FCF | 25.00 | EPS past 3/5Y | 94.97% 11.36% | ROIC | 8.71% | 52W Low | 196.49 21.69% | Perf 3Y | 4.24% |
| Dividend Est. | 2.76 (1.15%) | EV/EBITDA | 12.65 | Sales past 3/5Y | 9.38% 13.82% | Gross Margin | 44.43% | Volatility | 3.83% 2.63% | Perf 5Y | 8.96% |
| Dividend TTM | 2.52 (1.05%) | EV/Sales | 3.79 | EPS Y/Y TTM | 27.90% | Oper. Margin | 18.91% | ATR (14) | 7.05 | Perf 10Y | 237.65% |
| Dividend Ex-Date | Sep 04, 2026 | Quick Ratio | 2.96 | Sales Y/Y TTM | 8.70% | Profit Margin | 13.34% | RSI (14) | 66.78 | Recom | 2.15 |
| Dividend Gr. 3/5Y | 10.06% 9.28% | Current Ratio | 5.89 | EPS Q/Q | 21.98% | SMA20 | 6.77% | Beta | 0.91 | Target Price | 271.33 |
| Payout | 30.68% | Debt/Eq | 0.03 | Sales Q/Q | 7.22% | SMA50 | 10.41% | Rel Volume | 0.94 | Prev Close | 237.47 |
| Employees | 17,937 | LT Debt/Eq | 0.27 | Earnings | Nov 04 | SMA200 | 1.32% | Avg Volume | 851.27K | Price | 239.11 |
| IPO Date | Jun 01, 1992 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.65% -0.39% | Net Debt/EBITDA | -0.13 | Volume | 801,829 | Change | 0.69% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Initiated | UBS | Buy | $275 |
| May-21-26 | Reiterated | Piper Sandler | Overweight | $260 → $270 |
| May-13-26 | Reiterated | Keybanc | Overweight | $265 → $269 |
| Jul-15-25 | Upgrade | Morgan Stanley | Equal Weight → Overweight | |
| Oct-24-24 | Upgrade | Piper Sandler | Neutral → Overweight | $225 → $260 |
| Sep-03-24 | Reiterated | KeyBanc | Overweight | $255 → $265 |
| May-10-24 | Reiterated | Piper Sandler | Neutral | $225 |
| Apr-04-24 | Reiterated | Wolfe Research | $245 | |
| Apr-14-23 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Sep-23-22 | Downgrade | Needham | Buy → Hold |
Latest News
Aug-09-26
Aug-07-26
Aug-06-26
09:51AM
Aug-05-26
07:11PM
04:30PM
STERIS Announces Financial Results for Fiscal 2027 First Quarterglobenewswire.com
08:45AM
Jul-31-26
Jul-30-26
Jul-28-26
Jul-27-26
Jul-27-2604:30PM
09:45AM
Steris: A Good Moment To Buy Shares In This Sterilization Leaderseekingalpha.com
Company
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2026 3/31/2026 | FY 2025 3/31/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,037 | 5,936 | 5,460 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3,355 | 3,309 | 3,057 | — | — | — | — | — | — | |
| Gross Profit | 2,683 | 2,627 | 2,403 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,054 | 1,408 | 1,334 | — | — | — | — | — | — | |
| Research and Development | 116 | 113 | 108 | — | — | — | — | — | — | |
| Other Operating Expense | 371 | 4 | 94 | — | — | — | — | — | — | |
| Operating Income | 1,142 | 1,102 | 867 | — | — | — | — | — | — | |
| Interest Expense | 61 | 61 | 86 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | 6 | 16 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,090 | 1,047 | 796 | — | — | — | — | — | — | |
| Income Taxes | 282 | 262 | 185 | — | — | — | — | — | — | |
| Consolidated Net Income | 805 | 785 | 615 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 808 | 785 | 612 | — | — | — | — | — | — | |
| Net Income | 805 | 785 | 615 | — | — | — | — | — | — | |
| EPS (Recurring) | 8.20 | 7.93 | 6.24 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 8.20 | 7.93 | 6.24 | — | — | — | — | — | — | |
| EPS (Diluted) | 8.18 | 7.93 | 6.20 | — | — | — | — | — | — | |
| EBITDA | 1,810 | 1,595 | 1,359 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 29.23 | 27.89 | 36.56 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.88 | 3.65 | 4.11 | — | — | — | — | — | — | |
| Gross Margin | 44.44 | 44.26 | 44.01 | — | — | — | — | — | — | |
| Operating Margin | 18.92 | 18.56 | 15.88 | — | — | — | — | — | — | |
| Net Margin | 13.33 | 13.22 | 11.26 | — | — | — | — | — | — | |
| Shares Outstanding | 98 | 98 | 99 | — | — | — | — | — | — | |
| Market Capitalization | 23,433 | 21,671 | 22,438 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sohi Mohsen | Director | Jul 01 '26 | Option Exercise | 71.40 | 3,781 | 269,963 | 26,142 | Jul 02 |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | Jun 15 '26 | Sale | 209.28 | 1,419 | 296,968 | 35,259 | Jun 16 |
| Carestio Daniel A | President and CEO | Jun 05 '26 | Sale | 212.00 | 1,374 | 291,288 | 63,647 | Jun 08 |
| Carestio Daniel A | President and CEO | Jun 04 '26 | Sale | 214.64 | 3,054 | 655,511 | 65,021 | Jun 08 |
| Burton Karen L | Sr. Vice Pres., CFO | Jun 02 '26 | Option Exercise | 209.76 | 66 | 13,844 | 13,464 | Jun 04 |
| Breeden Richard C | Director | Jun 02 '26 | Option Exercise | 71.40 | 3,781 | 269,963 | 40,445 | Jun 04 |
| Breeden Richard C | Director | Jun 02 '26 | Sale | 209.51 | 1,481 | 310,284 | 38,964 | Jun 04 |
| FELDMANN CYNTHIA L | Director | Mar 05 '26 | Option Exercise | 152.32 | 3,098 | 471,887 | 3,803 | Mar 06 |
| FELDMANN CYNTHIA L | Director | Mar 05 '26 | Sale | 237.21 | 3,098 | 734,877 | 705 | Mar 06 |
| Madsen Julia | Sr. VP and GM, Life Sciences | Nov 21 '25 | Sale | 262.00 | 2,136 | 559,632 | 10,710 | Nov 25 |
| Madsen Julia | Sr. VP and GM, Life Sciences | Nov 21 '25 | Option Exercise | 128.22 | 5,008 | 642,139 | 13,582 | Nov 25 |
| Tamaro Renato | V.P. & Corporate Treasurer | Nov 18 '25 | Sale | 257.55 | 5,036 | 1,297,039 | 5,695 | Nov 20 |
| Tamaro Renato | V.P. & Corporate Treasurer | Nov 18 '25 | Option Exercise | 182.22 | 3,536 | 644,330 | 10,731 | Nov 20 |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | Nov 11 '25 | Sale | 265.14 | 15,000 | 3,977,100 | 33,669 | Nov 13 |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | Nov 11 '25 | Option Exercise | 69.72 | 15,000 | 1,045,800 | 48,669 | Nov 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.